iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Rhea-AI Summary

iBio (NASDAQ: IBIO) reported new preclinical data for IBIO-610, an Activin E antibody for fat-selective weight loss and maintenance. In obese non-human primates, IBIO-610 showed an extended half-life of 33.2 days. Using allometric scaling, iBio projects a predicted human half-life up to 100 days, potentially enabling dosing as infrequently as once every six months. Prior mouse data reportedly showed fat-selective, GLP-1-synergistic weight loss and prevention of weight regain after GLP-1 discontinuation. The NHP pharmacokinetic data and mechanistic preclinical results will be presented at ObesityWeek 2025.

Positive

• NHP half-life measured at 33.2 days
• Predicted human half-life up to 100 days
• Potential for twice-yearly dosing
• Fat-selective weight-loss mechanism in mice
• Demonstrated GLP-1 synergy and prevention of weight regain in mice

Negative

• Data are preclinical (mouse and non-human primate) not clinical
• Human half-life is a prediction based on scaling models, not measured in humans

Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation

New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only twice-yearly dosing

Extended half-life data and differentiated mechanism of action reinforce IBIO-610’s potential as a leading next-generation therapy for obesity and cardiometabolic disease

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data. The new data demonstrates an extended half-life of 33.2 days in NHPs and a predicted human half-life of up to 100 days, suggesting the potential for dosing as infrequently as twice per year. The findings will be presented by Cory Schwartz, Ph.D., Director of Research and Early Development of iBio, during an oral session at ObesityWeek^® 2025, taking place November 4–7 in Atlanta.

“GLP-1 therapies have transformed the treatment for obesity, but gaps in patient care remain for durable options addressing biology beyond appetite control,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “Our AI-enabled discovery platform has accomplished what was long considered extremely difficult - creating potentially a first-in-class long-acting antibody against Activin E. We believe this modality offers deep, sustained pathway blockade with infrequent dosing while leveraging the scalability and reliability of the global antibody manufacturing infrastructure. These advances underscore the differentiated potential of IBIO-610 and the broader power of our platform to unlock challenging, next-generation targets in obesity and cardiometabolic disease.”

The pharmacokinetic data, to be presented at ObesityWeek, demonstrates IBIO-610 has an extended half-life in obese non-human primates of 33.2 days. Based on an allomeric scaling model of half-life extended antibodies^1,2, it is predicted IBIO-610 will have a half-life in humans of up to 100 days, reducing the dosing frequency to once every six months, which has the potential to significantly improve patient experience.

“We are encouraged by these findings, as the combination of extended half-life and strong mechanistic validation in our mouse models underscores the differentiated profile of IBIO-610,” said Dr. Schwartz. “We believe that antibody-mediated targeting of Activin E has the potential to enable more comprehensive pathway modulation than other therapeutic approaches for the treatment of obesity. With its long-acting profile and fat-selective biology, IBIO-610 could not only promote fat-selective weight loss but also serve as an option for individuals transitioning off GLP-1 therapies, helping them maintain results without frequent injections, daily pills, or the side effects associated with GLP-1 agonism.”

References

1. Nakamura G, Ozeki K, Nagayasu M, Nambu T, Nemoto T, Hosoya KI. Predicting Method for the Human Plasma Concentration-Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates. Biol Pharm Bull. 2020;43(5):823-830. doi: 10.1248/bpb.b19-01042. PMID: 32378559.
2. Haraya K, Tachibana T. Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations. BioDrugs. 2023 Jan;37(1):99-108. doi: 10.1007/s40259-022-00566-2. Epub 2022 Nov 30. PMID: 36449140; PMCID: PMC9709760.

About iBio, Inc.

iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the therapeutic potential of Activin E as a target for cardiometabolic disorders and obesity; IBIO-610 preclinical data predicting human half-life of up to 100 days, suggesting the potential for dosing as infrequently as twice per year; the presentation of preclinical data during an oral session at ObesityWeek 2025; the Company’s AI-enabled discovery platform creating a potentially first-in-class long-acting antibody against Activin E, offering a deep, sustained pathway blockade with infrequent dosing while leveraging the scalability and reliability of the global antibody manufacturing infrastructure; the potential of IBIO-610 and the broader power of the Company’s platform to unlock challenging, next-generation targets in obesity and cardiometabolic disease; IBIO-610 having a half-life in humans of up to 100 days, reducing the dosing frequency to once every six months, potentially significantly improving patient experience; the potential of the antibody-mediated targeting of Activin E to enable more comprehensive pathway modulation than other therapeutic approaches for the treatment of obesity; and the ability of IBIO-610 to promote fat-selective weight loss and to serve as an option for individuals transitioning off GLP-1 therapies, helping them maintain results without frequent injections, daily pills, or the side effects associated with GLP-1 agonism. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of Activin E to be a successful target for cardiometabolic disorders and obesity; the Company’s AI-enabled discovery platform creating a potentially first-in-class long-acting antibody against Activin E, offering a deep, sustained pathway blockade with infrequent dosing while leveraging the scalability and reliability of the global antibody manufacturing infrastructure; the ability of IBIO-610 to promote fat-selective weight loss and to serve as an option for individuals transitioning off GLP-1 therapies, helping them maintain results without frequent injections, daily pills, or the side effects associated with GLP-1 agonism; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com

Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

An infographic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8409baa1-4ca8-43aa-b73d-84c2863ed6da

FAQ

What did iBio announce about IBIO-610 half-life on October 30, 2025?

iBio reported a 33.2-day half-life in obese NHPs and a predicted human half-life up to 100 days.

Could IBIO-610 dosing be as infrequent as twice yearly for IBIO (IBIO)?

iBio projects dosing once every six months based on a predicted human half-life up to 100 days.

How does IBIO-610 interact with GLP-1 therapies according to iBio data?

Preclinical mouse data show GLP-1-synergistic fat-selective weight loss and prevention of weight regain after GLP-1 stop.

Will IBIO-610 results presented at ObesityWeek 2025 include human data for IBIO (IBIO)?

No; the presentation will cover preclinical NHP pharmacokinetics and prior mouse mechanistic data, not human clinical results.

What is the basis for iBio's predicted 100-day human half-life for IBIO-610?

The prediction is based on allometric scaling models for half-life-extended antibodies cited by iBio.

Does iBio claim IBIO-610 is first-in-class for IBIO (IBIO)?

iBio describes IBIO-610 as potentially first-in-class for an Activin E antibody based on preclinical data.